Article
BRAF as a target for cancer therapy.
Anti-cancer agents in medicinal chemistry - 1 Mar 2011
Dienstmann Rodrigo, Tabernero Josep
Abstract excerpt
Tumors with mutations in the gene encoding the serine-threonine protein kinase BRAF are dependent on the MAPK signaling pathway for their growth, what offers an opportunity to test oncogene-targeted therapy. Mutations at the position V600 of BRAF were described in approximately 8% of all solid tumors, including 50% of melanomas, 30 to 70% of papillary thyroid carcinomas and 5 to 8% of colorectal adenocarcinomas....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.